Ibrance® (palbociclib)
for Breast Cancer

Ibrance (palbociclib) is a targeted therapy for HR-positive, HER2-negative metastatic breast cancer. It is used with an aromatase inhibitor or fulvestrant, depending on prior treatment. By inhibiting CDK 4 and 6, proteins that promote cancer cell growth, Ibrance helps slow disease progression. It is a CDK 4/6 inhibitor, not chemotherapy.

Heart
Other top medicines used to treat Breast Cancer